<DOC>
	<DOCNO>NCT01438749</DOCNO>
	<brief_summary>This randomize , placebo- active-controlled , crossover study evaluate abuse liability potential RO4917838 recreational drug user . In pre-study ( Part 1 ) , subject receive single dose either diazepam placebo inpatient crossover design , wash-out period least 10 day treatment . Subjects clearly able distinguish positive control placebo enrol main study ( Part 2 ) randomize single oral dos RO4917838 ( 3 dose level ) , diazepam placebo double-blind , double-dummy inpatient crossover design . Washout-periods 5 treatment period Part 2 least 10 day .</brief_summary>
	<brief_title>A Study The Abuse Liability Potential RO4917838 Recreational Drug Users</brief_title>
	<detailed_description />
	<mesh_term>Diazepam</mesh_term>
	<criteria>Healthy male female volunteer , 18 55 year age inclusive Recreational drug abuse experience ( &gt; /= 10 time lifetime abuse CNS depressant , &gt; /= 1 abuse CNS depressant previous 3 month Body mass index ( BMI ) 18 30 kg/m2 inclusive Main study ( Part 2 ) : Able differentiate diazepam placebo History significant disease disorder History current diagnosis substance dependence ( exclude caffeine nicotine ) Currently seek history participate treatment substancerelated disorder , include successful completion treatment Any confirm significant allergic reaction drug , multiple allergy judgement investigator Positive hepatitis B , hepatitis C HIV infection Pregnant lactate woman Participation investigational drug device study within last 30 day prior Day 1 study Confirmed positive drug screen screen / Day 1 ( allow positive THC screen Day 1 positive benzodiazepine screen ) Positive alcohol breath test screen / Day 1 Heavy smoker ( &gt; 20 cigarette , &gt; 8 pipeful &gt; 8 cigar per day )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>